Article Text

Download PDFPDF

Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial
  1. George D Kalliolias1,
  2. Panagiotis E Georgiou2,
  3. Ioannis A Antonopoulos3,
  4. Andrew P Andonopoulos3,
  5. Stamatis-Nick C Liossis3
  1. 1Division of Rheumatology, Department of Medicine, University of Patras Medical School and Patras University Hospital, Rion, Patras, Greece
  2. 2Division of Rheumatology, Agios Andreas Hospital, Patras, Greece
  3. 3Division of Rheumatology, Department of Medicine, University of Patras Medical School and Patras University Hospital, Rion, Patras, Greece
  1. Correspondence to:
    Dr S-N C Liossis
    Department of Medicine, Patras University Hospital, GR 26504 Rion, Patras, Greece;sliossis{at}

Statistics from

Adult-onset Still’s disease (AOSD) is characterised by a group of clinical and laboratory findings indicating systemic inflammation.1 Recent data support the hypothesis that interleukin 1 is essential in mediating inflammation, particularly in recalcitrant AOSD.2,3

From December 2003 we treated 10 patients with AOSD diagnosed according to proposed criteria.4 Four of these 10 consecutive patients, 4 had refractory AOSD with persistently active disease, despite administration of high-dose steroids. Herein, we report that all four patients rapidly responded to administration of anakinra (100 mg/day) and were promptly weaned from high-dose steroids. Table 1 shows the patients’ demographics, clinical and laboratory features and response to anakinra. Furthermore, patient 1 developed a life-threatening macrophage activation syndrome during the course of the disease, whereas patient 3 was refractory to methotrexate and etanercept.

Table 1

 Patients’ demographics, clinical and laboratory characteristics and response to anakinra treatment

In all four patients systemic symptoms disappeared within a few hours after the first injection of anakinra. Moreover, fever, fatigue, myalgias and arthralgias relapsed in patient 1 within a few days on discontinuation of anakinra and resolved again within hours after anakinra reinstitution. Polyarthritis in patient 3 improved in 24 h after administration of anakinra. Inflammatory markers (white blood cells, platelet count, erthrocyte sedimentation rate, C reactive protein and ferritin levels) reverted to normal within 2–4 weeks; liver enzyme increases normalised within 3 weeks (table 1). Apart from a self-limited injection-site erythema (present in all four patients), we recorded no other adverse events during the follow-up period (5–17 months). Initiation of anakinra treatment was the factor that permitted for fast and uneventful steroid tapering in our patients, and, in particular, patients 1, 2 and 4 totally discontinued steroid intake. In all patients, remission could not be maintained on low steroid doses and, in fact, all four patients had a suboptimal clinical and biochemical response even to high (40–60 mg/day prednisolone) steroid doses. Three of the four patients required readmissions to hospital to control relapses with intravenous pulsed methylprednisolone. Sustained high daily prednisolone doses led to the development of Cushing’s syndrome in patients 1, 2 and 3, a side effect that promptly subsided after the fast steroid tapering, achieved after the introduction of anakinra.

Despite the lack of randomised controlled trials, the impressive efficacy, the steroid-sparing effect and the good tolerance of anakinra in cases of refractory AOSD, combined with the limited efficacy and/or intolerance of anti-tumour necrosis factor-α regimens,5 suggest that interleukin 1R antagonism may represent a preferred treatment for patients with refractory AOSD. The steroid-sparing effect of anakinra in our patients represents a notable advantage of this treatment. We report, for the first time, such a striking steroid-sparing effect of anakinra treatment in patients with AOSD. Our study, although limited to four patients, adds to the similarly limited existing published literature.3,6,7 Despite rarity of AOSD, we suggest that larger clinical trials are important to evaluate the role of anakinra in the treatment of this disease.



  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.